Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.
The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.
Among the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。